0.620
0.03 (4.80%)
| Penutupan Terdahulu | 0.591 |
| Buka | 0.605 |
| Jumlah Dagangan | 24,547 |
| Purata Dagangan (3B) | 166,334 |
| Modal Pasaran | 3,734,352 |
| Harga / Buku (P/B) | 4.11 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -1.81 |
| Nisbah Semasa (MRQ) | 0.930 |
| Aliran Tunai Operasi (OCF TTM) | -5.56 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -6.49 M |
| Pulangan Atas Aset (ROA TTM) | -412.80% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Channel Therapeutics Corporatio | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.63 |
|
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 80.76% |
| % Dimiliki oleh Institusi | 7.07% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 20 Dec 2024 | Pengumuman | Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine |
| 18 Dec 2024 | Pengumuman | Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model |
| 21 Nov 2024 | Pengumuman | Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates |
| 29 Oct 2024 | Pengumuman | Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain |
| 28 Oct 2024 | Pengumuman | Chromocell to Present at Upcoming Fall Investor Conferences |
| 24 Oct 2024 | Pengumuman | Chromocell Announces Amendment to Stock Repurchase Plan |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |